<DOC>
	<DOC>NCT02073682</DOC>
	<brief_summary>Edoxaban will be similar to dalteparin in preventing recurrence of acute VTE following an initial index event in cancer subjects.</brief_summary>
	<brief_title>Cancer Venous Thromboembolism (VTE)</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>Male or female subjects with age â‰¥ 18 years or the otherwise legal lower age according to the country of residence; Confirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated; Cancer, other than basalcell or squamouscell carcinoma of the skin; Able to provide written informed consent. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE; Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization; Active bleeding or high risk for bleeding contraindicating treatment with LMWH or edoxaban; Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>